Atopic Asthma Clinical Trial
Official title:
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Verified date | January 2023 |
Source | Aldeyra Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects with Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Status | Completed |
Enrollment | 8 |
Est. completion date | January 18, 2022 |
Est. primary completion date | January 18, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Male or non-pregnant female, between 18 to 65 years of age (inclusive) at Screening Visit. - Subjects must give their signed and dated written informed consent (in English) to participate prior to commencing any study-related activities and must be willing to comply with study procedures, study restrictions, study protocol, and return for the required assessments. - Female subjects of either non-childbearing potential or of child-bearing potential who commit to consistent and correct use of at least one highly effective or two effective forms of contraception starting at least 4 weeks prior to the Screening Visit and for at least 30 days post last dose of study drug. - Generally healthy subjects with mild controlled asthma for 2 years at Screening Visit according to the Global Initiative for Asthma criteria. Exclusion Criteria: - History and presence of clinically significant cardiovascular, renal, neurologic, hepatologic, endocrinologic, gastrointestinal, genitourinary, autoimmune, hematological, or metabolic disease other than asthma, which in the opinion of Investigator may either put the subject at risk or influence the results during the study. - Positive skin prick test to other perennial allergens (i.e., mold, dog with = 3 mm wheal compared to negative control). Subjects with seasonal allergy symptoms that occur or are anticipated to occur during the study should result in subject exclusion or rescheduling until the subject is out of the allergy season. - Any relevant pulmonary disease within 1 year prior to dosing at the discretion of the investigator. - Recent hospitalization with asthma in the last 6 months or any other medical condition that the Investigator deems incompatible with participation in the trial. |
Country | Name | City | State |
---|---|---|---|
Canada | Cliantha Research | Mississauga | Ontario |
Lead Sponsor | Collaborator |
---|---|
Aldeyra Therapeutics, Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of ADX-629 in subjects with allergen-induced mild asthma | Safety, as assessed by adverse events (AEs) and serious adverse events (SAEs) | Safety assessment period (Day 1 through Day 75) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01448954 -
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma
|
Phase 2 | |
Withdrawn |
NCT01049178 -
Randomized Controlled Trial of Silymarin in Asthma
|
Phase 2/Phase 3 | |
Terminated |
NCT00644514 -
Genetics of Asthma - Bronchoscopy Studies
|
Phase 1 | |
Completed |
NCT00784459 -
The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
|
Phase 2 | |
Completed |
NCT00861211 -
Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
|
Phase 2 | |
Terminated |
NCT00671593 -
Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge
|
Phase 1 | |
Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
Completed |
NCT01420003 -
Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
|
N/A | |
Completed |
NCT02758548 -
Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects
|
Phase 2 | |
Completed |
NCT01179256 -
Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma
|
N/A | |
Completed |
NCT01545245 -
Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants
|
N/A | |
Completed |
NCT03603522 -
Probiotics and Capsaicin Evoked Coughs
|
N/A | |
Recruiting |
NCT03928431 -
Restoration of Microbiota in Neonates
|
N/A | |
Completed |
NCT02327234 -
Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma
|
N/A | |
Completed |
NCT01890161 -
A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma
|
Phase 2 | |
Completed |
NCT03665701 -
Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites
|
N/A | |
Completed |
NCT04397081 -
Atopic Diseases & Human Papilloma Virus
|